Article
ASCO GU: AstraZeneca, Merck's Lynparza one-ups J&J's Zejula with prostate cancer win regardless of gene mutations
Rating:
0.0
Views:
61
Likes:
1
Library:
1
AstraZeneca and Merck & Co.'s Lynparza may have a narrower label than GlaxoSmithKline's rival drug Zejula in ovarian cancer, but in prostate cancer, the situation could flip.< | AstraZeneca and Merck & Co.'s Lynparza may have a narrower label than GlaxoSmithKline's rival drug Zejula in ovarian cancer, but in prostate cancer, the situation could flip.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value